ProLynx, Inc.
Biotechnology company · San Francisco, California, United States
ProLynx, Inc. is a biotechnology company headquartered in San Francisco, California, United States. Its earliest recorded incorporation is in 2019. It has received 4 US government small-business research awards (SBIR/STTR) from health agencies, $689,054 in total, most recently in 2020. It has reported private securities offerings to the US SEC, most recently $55,244 sold in a notice filed in 2020.
ProLynx at a glance
What does ProLynx do?
US government research funding
4 SBIR/STTR small-business research awards from US health agencies, $689,054 in total (2010 to 2020). NIH funding came from the National Institute of Diabetes and Digestive and Kidney Diseases.
Private fundraising reported to the SEC
1 Form D notice; the most recent reported $55,244 sold (2020).
Frequently asked questions about ProLynx
Where is ProLynx headquartered?
ProLynx, Inc. is headquartered in San Francisco, California, United States.
What does ProLynx do?
ProLynx, Inc. is a biotechnology company.
When was ProLynx founded?
The earliest incorporation on record for ProLynx, Inc. is in 2019, according to public company registers.
Similar companies
- Ossium Health, Inc.San Francisco, California, United States
- Vir Biotechnology, Inc.San Francisco, California, United States
- Titan Pharmaceuticals IncSan Francisco, California, United States
- Senti Biosciences, Inc.San Francisco, California, United States
- Amygdala Neurosciences IncSan Francisco, California, United States
- Excision BioTherapeutics IncSan Francisco, California, United States
- Second Genome, Inc.San Francisco, California, United States
- Revel Pharmaceuticals Inc.San Francisco, California, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-25. Data licences